Volume 4.28 | Jul 23

Hematopoiesis News 4.28 July 23, 2013
Hematopoiesis News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Hematopoiesis News on Twitter
Keeping the Reserve Force Home
Hematopoietic stem cells come in two flavors: the reserve force sits quietly waiting to be called upon while the active arm continually proliferates spawning billions of blood cells every day. Researchers revealed a new mechanism that is critical in maintaining the delicate balance between the two. The team reports that genomic imprinting, a process that specifically shuts down one of the two gene copies found in each mammalian cell, prevents the reservists from being called up prematurely. [Press release from the Stowers Institute for Medical Research discussing online prepublication in Nature] Press Release | Abstract
Learn how to complete, submit and review BMT registry forms locally. Join the Webinar.
PUBLICATIONS (Ranked by impact factor of the journal)

Positive Feedback between PU.1 and the Cell Cycle Controls Myeloid Differentiation
Regulatory gene circuits with positive feedback loops control stem cell differentiation, but several mechanisms can contribute to positive feedback. Researchers dissected feedback mechanisms through which the transcription factor PU.1 controls lymphoid and myeloid differentiation. [Science] Abstract

Antagonistic Regulation by the Transcription Factors C/EBPα and MITF Specifies Basophil and Mast Cell Fates
The authors identified a population of granulocyte-macrophage progenitors that were highly enriched in the capacity to differentiate into basophils and mast cells while retaining a limited capacity to differentiate into myeloid cells. They designated these progenitor cells pre-basophil and mast cell progenitors. [Immunity] Abstract | Graphical Abstract

Meta-Analysis of IDH-Mutant Cancers Identifies EBF1 as an Interaction Partner for TET2
Isocitrate dehydrogenase (IDH) genes 1 and 2 are frequently mutated in acute myeloid leukemia (AML), low-grade glioma, cholangiocarcinoma (CC) and chondrosarcoma. For AML, low-grade glioma and CC, mutant IDH status is associated with a DNA hypermethylation phenotype, implicating altered epigenome dynamics in the etiology of these cancers. By analyzing sequence motifs surrounding hypermethylated sites across the four cancer types, and using chromatin immunoprecipitation and western blotting, researchers identified the transcription factor EBF1 (early B-cell factor 1) as an interaction partner for TET2, suggesting a sequence-specific mechanism for regulating DNA methylation. [Nat Commun] Full Article

Mouse Extra-Embryonic Arterial Vessels Harbor Precursors Capable of Maturing into Definitive HSCs
Investigators showed that umbilical cord and vitelline arteries, but not veins, contain pre-hematopoietic stem cells (HSCs) capable of maturing into definitive HSCs in the presence of exogenous IL3, although in fewer numbers than the aorta-gonad-mesonephros region, and that pre-HSC activity in vitelline arteries increases with proximity to the embryo proper. [Blood] Abstract

Intestinal Bacteria Modify Lymphoma Incidence and Latency by Affecting Systemic Inflammatory State, Oxidative Stress, and Leukocyte Genotoxicity
Using an ataxia-telangiectasia mouse model, scientists compared lymphoma incidence in several isogenic mouse colonies harboring different bacterial communities, finding that intestinal microbiota are a major contributor to disease penetrance and latency, lifespan, molecular oxidative stress, and systemic leukocyte genotoxicity. [Cancer Res] Abstract | Press Release

Hoxb8 Regulates Expression of MicroRNAs to Control Cell Death and Differentiation
Hoxb8 overexpression immortalizes hematopoietic progenitor cells in a growth-factor-dependent manner and co-operates with interleukin-3 (IL-3) to cause acute myeloid leukemia. To further understand how Hoxb8 contributes to myeloid cell immortalization, researchers generated IL-3-dependent myeloid cells expressing Hoxb8 under the control of an inducible promoter. [Cell Death Differ] Abstract

Fbw7-Dependent Cyclin E Regulation Ensures Terminal Maturation of Bone Marrow Erythroid Cells by Restraining Oxidative Metabolism
The authors examined the physiologic consequences of cyclin E dysregulation in bone marrow erythroid cells during terminal maturation in vivo. [Oncogene] Abstract


Global Burden of Sickle Cell Anemia in Children under Five, 2010–2050: Modeling Based on Demographics, Excess Mortality, and Interventions
Investigators aimed to estimate trends in the future number of newborns with sickle cell anemia (SCA) and the number of lives that could be saved in under-five children with SCA by the implementation of different levels of health interventions. [PLoS Med] Full Article | Press Release

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core-Binding Factor Leukemia
In a cohort of 84 de novo AML patients with a CBFB/MYH11 rearrangement and in 36 patients with a RUNX1/RUNX1T1 rearrangement, the FLT3 N676K mutation was identified in five and one patients, respectively (5/84, 6%; 1/36, 3%). [Blood] Abstract

STAT3 Mutations Identified in Human Hematological Neoplasms Induce Myeloid Malignancies in a Mouse Bone Marrow Transplantation Model
Researchers investigated the mutational status of STAT3 in a large series of patients with lymphoid and myeloid diseases. Data indicate that the STAT3Y640F mutation leads to constitutive activation of STAT3, induces malignant hematopoiesis in vivo and may represent a novel therapeutic target in some lymphoid malignancies. [Haematologica] Abstract | Full Article

Register for new mouse/rat HSC CFU training course.
Immunotherapeutic Strategies for Relapse Control in Acute Myeloid Leukemia
The authors review past and present strategies for relapse control with focus on overcoming leukemia-related immunosuppression in acute myeloid leukemia. [Blood Rev] Abstract

Biomarkers for Determining the Prognosis in Chronic Myelogenous Leukemia
This review presents the supporting data and discusses how certain clinical characteristics at diagnosis, the depth of early response, the presence of certain kinase domain mutations, and additional molecular changes serve as prognostic factors that may guide individualized treatment decisions for patients with chronic myelogenous leukemia in chronic phase. [J Hematol Oncol] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.  
Seattle Genetics Initiates Phase I Trial of SGN-CD33A in Acute Myeloid Leukemia (AML)
Seattle Genetics, Inc. announced initiation of a phase I clinical trial of SGN-CD33A for patients with AML. SGN-CD33A is a novel antibody-drug conjugate (ADC) utilizing Seattle Genetics’ newest ADC technology targeted to CD33, which is expressed on most AML cells. The CD33 antibody is attached to a highly potent cytotoxic DNA-crosslinking agent, a pyrrolobenzodiazepine dimer, via a proprietary site-specific conjugation technology to a monoclonal antibody with engineered cysteines. The trial is designed to assess the safety and anti-leukemia activity of SGN-CD33A. [Seattle Genetics, Inc.] Press Release

Celgene Will Discontinue Phase III ORIGIN® Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Celgene Corporation announced that after consultation with the U.S. Food and Drug Administration Celgene will discontinue treatment with REVLIMID® (lenalidomide) in the open-label, phase III ORIGIN® trial, which enrolled 450 patients in over 100 sites in 26 countries. An imbalance was observed in the number of deaths in patients treated with lenalidomide versus patients treated with chlorambucil. [Celgene Corporation]
Press Release

STEMSOFT Announces Release of CIBMTR Upload Interface
STEMSOFT Software Inc. announced the release of the new CIBMTR upload interface, STEMSOFTconnect: REGISTRY. This new solution is designed to allow users to complete, submit and review all AGNIS-defined registry forms locally for seamless upload to the Center for International Blood and Marrow Transplant Research (CIBMTR®). [STEMSOFT Software Inc.] Press Release

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)  
NEW 3rd Geneocell Summer School: Advanced Stem Cell Technologies & Therapies
September 9-15, 2013
Izmit, Turkey

Visit our events page to see a complete list of events in the hematopoiesis research community.
NEW Postdoctoral Position – Computational Analysis of Genome-Wide Data of Normal and Malignant Blood Cells (University of Copenhagen, Department of Biomedical Sciences)

Postdoctoral Position – Stem Cell Biology (St. Jude Children’s Research Hospital)

Postdoctoral Fellow – Cancer Stem Cell Biology (McGill University)

Postdoctoral Position – Hematopoietic Differentiation of Pluripotent Stem Cells (Center for Physiology and Pathophysiology, University of Cologne)

Research Associate (Assistant Professor) – Pediatric Hematology/Oncology (The University of Chicago)

Postdoctoral Research Fellow – Hematology/Pharmacology (Thomas Jefferson University, Cardeza Foundation for Hematologic Research)

Postdoctoral Positions – Stem Cell Biology and Epigenetics (University of Wisconsin-Madison)

Director of Cell Processing Facility (S L Collins Associates, Inc.)

PhD Student Position – Hematopoietic Stem Cells (Katholieke Universiteit Leuven)

Postdoctoral Researcher – Hematopoietic Stem Cells (Albert Einstein College of Medicine)

Studentship – Novel Mechanisms in Blood Cancers Drug-Resistance (University of East Anglia)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.
Learn more about Hematopoiesis News: Archives | Events | Contact Us